Cochrane · systematic review · CD010816
Bortezomib for the treatment of multiple myeloma
Scott, K, Hayden, PJ, Will, A, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
25
current version
GRADE rated
24
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 4%Very low 1 · 4%Low 9 · 36%Moderate 7 · 28%High 7 · 28%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Bortezomib versus no bortezomib for the treatment of multiple myeloma
Population: All patients with a diagnosis of multiple myeloma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall Survival Bortezomib vs no bortezomib | Odds Ratio 0.77 [0.69, 0.86] | 9 studies · 4118 participants | High |
Overall Survival ‐ Bortezomib versus no bortezomib (same background therapy) Bortezomib vs no bortezomib | Odds Ratio 0.77 [0.65, 0.92] | 4 studies · 1586 participants | Moderate Downgraded: inconsistency |
Overall Survival ‐ Bortezomib versus no bortezomib (different background therapy or other agents) Bortezomib vs no bortezomib | Odds Ratio 0.76 [0.67, 0.88] | 5 studies · 2532 participants | High |
Progression‐Free Survival Bortezomib vs no bortezomib | Odds Ratio 0.67 [0.61, 0.72] | 9 studies · 4344 participants | Low Downgraded: imprecision, inconsistency |
Progression‐Free Survival ‐ Bortezomib versus no bortezomib (same background therapy) Bortezomib vs no bortezomib | Odds Ratio 0.65 [0.57, 0.74] | 5 studies · 1855 participants | Moderate Downgraded: imprecision, inconsistency |
Progression‐Free Survival ‐ Bortezomib versus no bortezomib (different background therapy or other agents) Bortezomib vs no bortezomib | Odds Ratio 0.67 [0.61, 0.75] | 4 studies · 2489 participants | Low Downgraded: imprecision, inconsistency |
Treatment‐related death Bortezomib vs no bortezomib | OR 0.76 [0.43, 1.34] | 5 studies · 2389 participants | Low Downgraded: imprecision, inconsistency |
Treatment‐related death ‐ Bortezomib versus no bortezomib (same background therapy) Bortezomib vs no bortezomib | OR 0.81 [0.3, 2.16] | 2 studies · 737 participants | Low Downgraded: imprecision, inconsistency |
Treatment‐related death ‐ Bortezomib versus no bortezomib (different background therapy or other agents) Bortezomib vs no bortezomib | OR 0.73 [0.36, 1.48] | 3 studies · 1652 participants | Very low Downgraded: imprecision, inconsistency |
Health‐related quality of life Bortezomib vs no bortezomib | no estimate extracted | 4 studies · 717 participants | Ungraded |
Adverse Events: Thrombocytopenia Bortezomib vs no bortezomib | OR 2.05 [1.7, 2.48] | 8 studies · 3791 participants | Low Downgraded: imprecision, inconsistency |
Adverse Events: Thrombocytopenia ‐ Bortezomib versus no bortezomib (same background therapy) Bortezomib vs no bortezomib | OR 1.51 [1.13, 2] | 3 studies · 1196 participants | High |
Adverse Events: Thrombocytopenia ‐ Bortezomib versus no bortezomib (different background therapy or other agents) Bortezomib vs no bortezomib | OR 2.6 [2.01, 3.35] | 5 studies · 2595 participants | Low Downgraded: imprecision, inconsistency |
Adverse Events: Diarrhoea Bortezomib vs no bortezomib | OR 2.44 [1.74, 3.43] | 8 studies · 3788 participants | Low Downgraded: imprecision, inconsistency |
Adverse Events: Diarrhoea ‐ Bortezomib versus no bortezomib (same background therapy) Bortezomib vs no bortezomib | OR 6.24 [2.79, 13.98] | 4 studies · 1670 participants | Moderate Downgraded: imprecision, inconsistency |
Adverse Events: Diarrhoea ‐ Bortezomib versus no bortezomib (different background therapy or other agents) Bortezomib vs no bortezomib | OR 1.8 [1.22, 2.65] | 4 studies · 2118 participants | Moderate Downgraded: imprecision, inconsistency |
Adverse Events: Peripheral Neuropathy Bortezomib vs no bortezomib | OR 3.71 [2.92, 4.7] | 10 studies · 4636 participants | Moderate Downgraded: imprecision, inconsistency |
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (same background therapy) Bortezomib vs no bortezomib | OR 5.1 [3.37, 7.72] | 5 studies · 2040 participants | Low Downgraded: imprecision, inconsistency |
Adverse Events: Peripheral Neuropathy ‐ Bortezomib versus no bortezomib (different background therapy or other agents) Bortezomib vs no bortezomib | OR 3.09 [2.3, 4.14] | 5 studies · 2596 participants | High |
Adverse Events: Infections (All) Bortezomib vs no bortezomib | OR 1.51 [1.27, 1.79] | 9 studies · 4266 participants | Moderate Downgraded: imprecision, inconsistency |
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (same background therapy) Bortezomib vs no bortezomib | OR 1.37 [0.97, 1.93] | 4 studies · 1670 participants | High |
Adverse Events: Infections (All) ‐ Bortezomib versus no bortezomib (different background therapy or other agents) Bortezomib vs no bortezomib | OR 1.55 [1.27, 1.9] | 5 studies · 2596 participants | Low Downgraded: imprecision, inconsistency |
Adverse Events: Cardiac Disorders Bortezomib vs no bortezomib | OR 1.74 [1.17, 2.58] | 5 studies · 2191 participants | High |
Adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib (same background therapy) Bortezomib vs no bortezomib | OR 1.17 [0.39, 3.52] | 2 studies · 736 participants | Moderate Downgraded: imprecision, inconsistency |
Adverse Events: Cardiac Disorders ‐ Bortezomib versus no bortezomib (different background therapy or other agents) Bortezomib vs no bortezomib | OR 1.84 [1.21, 2.81] | 3 studies · 1455 participants | High |